Refinement of an Autocidal Gravid Ovitrap for mass-manufacturing

改进用于大规模生产的自杀妊娠产卵器

• 批准号: 9276569
• 负责人: Michael Gilbert Banfield
• 金额: $ 61.85万
• 依托单位: BANFIELDBIO INC.
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-07-01 至 2019-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9276569
• 关键词: Address; Adhesives; Adult; Aedes; Affect; Arboviruses; Area; Biological Assay; Breeding; Centers for Disease Control and Prevention (U.S.); Chemicals; Communicable Diseases; Computer-Aided Design; Country; Culicidae; Data; Dengue; Development; Devices; Diagnostic; Diagnostic Procedure; Disease; Disease Outbreaks; Dose; Ecosystem; Effectiveness; Elements; Exclusion; Female; Florida; Formulation; Frequencies; Funding; Geography; Goals; Gravid; Gravidity; Home environment; Individual; Industry; Infection; Infusion procedures; Injection of therapeutic agent; Insecticides; Lead; Life; Mission; Modification; Molds; Monitor; Mosquito Control; Neighborhoods; Performance; Persons; Pesticides; Phase; Population; Prevalence; Process; Production; Public Health; Puerto Rico; Quality of life; Quick Test for Liver Function; Regulation; Research; Risk; Seasons; Ships; Site; Source; Technology; Testing; Tropical Disease; United States National Institutes of Health; Vector-transmitted infectious disease; Virus Diseases; Water; Work; Yellow Fever; Zoonoses; base; chikungunya; commercialization; cost; cost effective; design; design and construction; digital; disorder control; efficacy testing; egg; field study; improved; killings; pesticide resistance; prevent; prototype; public health relevance; success; three-dimensional modeling; tool; transmission process; urban area; urban setting; user-friendly; vector; vector control; vector mosquito

 DESCRIPTION (provided by applicant): Lethal ovitraps are a modification of a common mosquito population monitoring technology: adult females are enticed to a water container to lay their eggs and are exposed to a lethal dose of pesticide. The Autocidal Gravid Ovitrap (AGO) improves this technology in several ways. It has been modified to make it more attractive to gravid Aedes aegypti. The killing agent is an adhesive, thus extending the useful field life while negating the need for insecticides. This project aims to modify the current AGO design to make it suitable for mass production. The goal is to produce an efficacious, cost-effective, and durable AGO. Long-term objectives include optimizing use of the AGO for control of arbovirus-vectoring mosquitoes to prevent outbreaks of dengue and other diseases, and extending the technology for use with other container-breeding species of mosquitoes. The final result is expected to be a commercially viable product for professional and home use. Phase I efforts culminated in a prototype injection mold for the AGO, with individual elements of the design validated both digitally and in competitive cage bioassays. Multiple synthetic attractants were evaluated, with several performing at least as well as the standard hay infusion. The Phase I AGO is suitable for mass production, cost-effective, user-friendly, and has high attraction to Ae. aegypti. Phase II will result in a product that can be mass-manufactured with demonstrated efficacy against container- breeding mosquitoes. The injection-molded AGO will be evaluated in large room and field tests for effectiveness and durability. The attractant formulation will be refined in arena ad field tests to be at least as attractive as hay infusion, and easily packaged and shipped. Large-scale urban field testing will be expanded to test the AGO's efficacy in suppressing both Ae. aegypti and Ae. albopictus. A CDC-developed diagnostic "quick test" will be used to determine disease frequency in trapped mosquitoes, to assess if large-scale deployment of the AGO reduces the mosquito population below the dengue transmission threshold. Container-breeding mosquitoes such as Ae. aegypti and Ae. albopictus are day-biting nuisance mosquitoes. They are also vectors of serious viral diseases, including dengue fever, yellow fever, and chikungunya. Currently >2.5 billion people in tropical countries are at risk of infection with dengue fever. The mission of the CDC-NCEZID is to detect, prevent, and control zoonotic infectious diseases. Dengue fever and chikungunya are not currently major threats to US residents, but these diseases are spreading as their mosquito vectors expand their ranges. The AGO will be both a monitoring tool to check the spread of these increasingly invasive species, and an effective control option for use in outbreaks by creating area-wide suppression of mosquito populations. It promises to be an important tool in the long term battle to control nuisance mosquitoes, improve quality of life for people in affected areas, and prevent vector-borne diseases.

 描述（由应用提供）：致命的卵子是对普通蚊子人口监测技术的修改：成年雌性被诱使饮水容器产卵，并暴露于致命的农药剂量。自动质膜卵形（AGO）以几种方式改进了这项技术。它已经进行了修改，以使其对Gratid Aedes Aegypti更具吸引力。杀戮剂是一种粘合剂，因此延长了有用的野生寿命，同时消除了对杀虫剂的需求。该项目旨在修改当前的AGO设计，以使其适合大规模生产。目标是产生有效，成本效益且耐用的目标 前。长期目标包括优化AGO用于控制Arbovirus-Vectoring蚊子以防止风扇和其他疾病的爆发，并扩展该技术以与其他集装箱繁殖物种一起使用。最终结果预计将是专业和家庭使用的商业可行产品。第一阶段的努力最终导致了AGO的原型注射模具，设计的个别要素在数字化和竞争性笼子生物测定中均得到了验证。评估了多个合成景点，至少有几种表现以及标准的干草输注。 IOGO阶段适合大规模生产，具有成本效益，用户友好，并且对AE具有很高的吸引力。埃及。第二阶段将导致可以通过对容器育种蚊子进行大规模制造的产品。注射以前的AGO将在大房间和现场测试中进行评估，以获得有效性和​​耐用性。吸引人的配方将在Arena AD现场测试中进行完善，至少与干草输注一样有吸引力，并且易于包装和运输。将扩大大规模的城市现场测试，以测试AGO在抑制AE方面的有效性。埃及和ae。白化病。 CDC开发的诊断“快速测试”将用于确定被困蚊子中的疾病频率，以评估AGO的大规模部署是否会减少登革热传播阈值以下的蚊子种群。集装箱繁殖的蚊子，例如AE。埃及和ae。白化病是日间刺激性蚊子。它们也是严重病毒疾病的媒介，包括登革热，黄热病和基孔肯尼亚。目前，热带国家有25亿人有登革热感染的风险。 CDC-NCEZID的任务是检测，预防和控制人畜共患感染疾病。登革热和基孔肯雅亚目前并不是对美国居民的主要威胁，但是随着蚊子向量扩大范围，这些疾病正在蔓延。 AGO将是检查这些日益侵入性物种的传播的监测工具，也将是通过在范围内抑制蚊子种群的有效控制选择。它有望成为控制滋扰蚊子，改善受影响地区人们的生活质量并防止媒介传播疾病的长期战斗中的重要工具。